We are conducting a phase II trial in untreated patients with advanced NSCLC EGFR-sensitizing mutation and performance status of 0 to 2….Patients are treated with aumolertinib 110mg orally perday plus pemetrexed 500mg/m2 and carboplatin...Preliminary overall ORR was 88.2% (30/34)...This is the first report that the combination of aumolertinib and chemotherapy provided a promising therapeutic strategy for advanced EGFR mutation NSCLC patients, even with CNS metastasis. And preliminary data from this trial suggests patients harboring EGFR exon19 deletion mutation and TP53 mutation would benefit more from this combination strategy (Table 1).